On-Demand Webinar: Innovations in Organoid Modeling for Disease Modeling and Cell Therapy
Overview
Explore the wide-ranging uses of 3D coculture models, spanning from immune checkpoint kinase (ICK) assays to tumor-infiltrating lymphocytes (TILs), natural killer (NK) cells, chimeric antigen receptor T (CAR-T) cells, and beyond, and see how these assays are transforming the landscape of cancer research. Delve into the world of live-cell imaging platforms as experts engage in discussions about the forefront of technology, weighing the advantages and disadvantages of each method. Understand the complexities of organoid modeling and gain essential insights into the innovations on the horizon. Additionally, benefit from the wisdom of leading experts who have successfully established 3D organoid coculture assays for disease modeling and cell therapies.
- Document type: Webinar
- Watch time: 1 hour
In This Webinar You Will Learn:
- Why organoids are better 3D models than other 2D cultures
- Key applications (coculture assays for oncology or I-O) using organoids and methods/ models used in this field
- New or existing technologies to support live-cell imaging and analysis
- Best practices and experiences for how to set up 3D organoid coculture assays for disease modeling or cell therapy
- Key values and benefits of organoid cultures in disease modeling
- Key applications of 3D coculture models
- Live-cell imaging platforms and methods
- Challenges and requirements for future innovations in organoid modeling
Webinar Speakers
Thomas Durcan
Director, Early Drug Discovery Unit (EDDU) and Associate Professor at McGill University
As Director of the Early Drug Discovery Unit (EDDU) (https://youtu.be/msNd3i75jxs) at the The Neuro and Associate Professor at McGill University, I oversee a team of 40+ research staff and students, committed to applying patient-derived stem cells towards the development of phenotypic discovery assays and 3D neuronal organoid models for neurodegenerative and neurodevelopmental disorders. Combined with new approaches in the group towards building multiomic profiles and predictive computational models with patient-derived IPSC cells, the long-term strategy over the next decade is to identify new personalized precision therapies that can be applied towards building clinical trials on a dish.
Sheraz Gul
Head of Drug Screening & Compound Repurposing, Fraunhofer
Sheraz is the Head of Assay Development and Drug Repurposing at the Fraunhofer Institute, Germany. He has professional experience in the field of drug discovery, assay development and screening gained whilst employed in academia. He has co-authored more than 80 peer-reviewed papers, book chapters and patents including the Enzyme Assays: Essential Data handbook. He also has an interest in education and thus far has organized 46 drug discovery workshops since 2011 across the globe and trained 880 scientists.
Natalie Luhtala
Senior Study Director, Crown Bioscience
A molecular and cancer cell biologist with over 15 years of research experience in basic scientific studies of RNA, lentiviral engineering, signaling pathways, and mouse models for cancer. Presently directing CRO-based lab research in San Diego – successfully led a team to implement automation, culturing of multiple organoids models, and combination and single agent treatment studies. Currently directing 2 IND level projects and a global interdepartmental lentiviral engineering study, applying my strong scientific and interpersonal skills to execute large, multidisciplinary studies that meet clients’ needs.
Vaidehi Joshi
Director, Viscient Bio Inc
Research scientist / leader with 10 years of experience in developing unique therapeutic solutions. Demonstrated ability to excel in innovative environments, while developing cutting-edge research products and cell-based therapies in early-stage biotech. Expertise includes participation in groundbreaking research in the areas of tissue engineering, 3D cell biology and biomaterials. Background in initial phases of pre-clinical development.